{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:21:44Z","timestamp":1788873704901,"version":"build-2803163510"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jdcr.2022.02.025","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T12:01:06Z","timestamp":1646913666000},"page":"64-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Amelioration of unstable vitiligo and normalization of thryroglobulin antibodies with oral tofacitinib"],"prefix":"10.1016","volume":"23","author":[{"given":"Angela Yen","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Cepica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samanna","family":"Maberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jdcr.2022.02.025_bib1","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1089\/acm.2020.0292","article-title":"A systematic review of nutrition, supplement, and herbal-based adjunctive therapies for vitiligo","volume":"27","author":"Shakhbazova","year":"2021","journal-title":"J Altern Complement Med"},{"issue":"1","key":"10.1016\/j.jdcr.2022.02.025_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2133.2012.11197.x","article-title":"Guidelines for the management of vitiligo: the European Dermatology Forum consensus","volume":"168","author":"Taieb","year":"2013","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jdcr.2022.02.025_bib3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jaad.2015.08.063","article-title":"Comorbid autoimmune diseases in patients with vitiligo: a cross-sectional study","volume":"74","author":"Gill","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2022.02.025_bib4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4161\/derm.19200","article-title":"When are laboratory tests indicated in patients with vitiligo?","volume":"4","author":"Rodr\u00edguez-Mart\u00edn","year":"2012","journal-title":"Dermatoendocrinol"},{"issue":"1","key":"10.1016\/j.jdcr.2022.02.025_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3343\/alm.2019.39.1.3","article-title":"Laboratory testing in thyroid conditions - pitfalls and clinical utility","volume":"39","author":"Soh","year":"2019","journal-title":"Ann Lab Med"},{"issue":"7","key":"10.1016\/j.jdcr.2022.02.025_bib6","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1080\/09546634.2018.1546043","article-title":"JAK-inhibitors in dermatology: current evidence and future applications","volume":"30","author":"Ciechanowicz","year":"2019","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"10.1016\/j.jdcr.2022.02.025_bib7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.adengl.2021.03.012","article-title":"Janus kinase inhibitors in dermatology: part 1 \u2014 general considerations and applications in vitiligo and alopecia areata","volume":"112","author":"Garcia-Melendo","year":"2021","journal-title":"Actas Dermo Sifiliogr\u00e1ficas (English Edition)"},{"issue":"6","key":"10.1016\/j.jdcr.2022.02.025_bib8","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/bjd.14416","article-title":"Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo","volume":"174","author":"Wang","year":"2016","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2022.02.025_bib9","doi-asserted-by":"crossref","first-page":"101388","DOI":"10.1016\/j.beem.2020.101388","article-title":"Graves' disease: clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy","volume":"34","author":"Antonelli","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512622001102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512622001102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:24:18Z","timestamp":1762475058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512622001102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":9,"alternative-id":["S2352512622001102"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2022.02.025","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amelioration of unstable vitiligo and normalization of thryroglobulin antibodies with oral tofacitinib","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2022.02.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}